A practical tool for predicting outcomes in essential thrombocythemia: Triple A risk model and beyond
The management of essential thrombocythemia (ET) relies on risk stratification; therefore, easily applicable risk scores with improved prognostic value are in demand. The Triple A risk score is a novel model incorporating age, absolute neutrophil, and absolute lymphocyte counts (AAA model). In this study, we aimed to evaluate the predictive performance of Triple A score in ET for survival and its complications in an independent cohort, in addition to refining the model by incorporating absolute monocyte count and neutrophil-to-lymphocyte ratio (NLR). Demographic, clinical, and laboratory data of 565 patients with ET were retrospectively collected. Based on Triple A score, 250 patients were classified as low risk, 228 as intermediate-1 risk, 37 as intermediate-2 risk, and 50 as high risk. Over a median follow-up of 6 years, 10.3% patients developed thrombosis, 4.4% experienced bleeding, 5.1% had post-ET myelofibrosis, and 10.9% died. There were significant differences in overall survival and thrombosis-free survival across risk groups. Monocytosis (>0.8 × 109/L) was associated with increased mortality and its prevalence increased progressively with higher Triple A scores. Elevated NLR was also linked to a higher risk of mortality, and moreover, NLR-monocyte-age-based risk score demonstrated significant differences in survival risk. Consequently, Triple A score is an easy-to-use and reliable tool for predicting survival and thrombosis in ET. Incorporating monocytosis into Triple A (AAA+A model) may further enhance its prognostic accuracy. NLR also demonstrated prognostic value both independently and as component of NLR-monocyte-age-based model, highlighting its potential as a robust tool for risk stratification.
Authors
- Mehmet Sönmez (ORCID: https://orcid.org/0000-0002-2176-4371)
- Abdülkadir Karışmaz (ORCID: https://orcid.org/0000-0002-5556-7501)
- Fehmi Hindilerden (ORCID: https://orcid.org/0000-0002-6297-9555)
- İpek Yönal Hindilerden (ORCID: https://orcid.org/0000-0003-1353-2367)
- Zeynep Atlı (ORCID: https://orcid.org/0000-0002-2959-0978)
- Ahmet Emre Eşkazan (ORCID: https://orcid.org/0000-0001-9568-0894)
- Özge Sönmez (ORCID: https://orcid.org/0000-0002-7433-4447)
- Teoman Soysal (ORCID: https://orcid.org/0000-0002-7417-2118)
- Esiyla Oyur
Institutions
- Karadeniz Technical University (TR)
- University of Health Science (KH)
- Istanbul University-Cerrahpaşa (TR)
- Bakırköy Dr.Sadi Konuk Eğitim ve Araştırma Hastanesi (TR)
- Sağlık Bilimleri Üniversitesi (TR)
- Istanbul Eye Hospital (TR)
- Istanbul University (TR)
- Sinop University (TR)
Publication Details
- Journal
- Blood Advances
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1182/bloodadvances.2025017896
- Citations
- 1
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.63